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Amyotrophic Lateral Sclerosis
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Abstract
The term motor neuron disease refers to several diseases affecting the motor 
neurons and is sometimes used interchangeably to refer to amyotrophic lateral 
sclerosis (ALS), which is the most common motor neuron disease. This chapter will 
focus on ALS. A complex combination of molecular pathways and cell interactions 
cause ALS. About 10% of ALS cases are genetic, although it has been hypothesized 
that as more genes are discovered to contribute to the disease, a larger percentage 
of cases will be quoted. This chapter discusses in detail the most common genetic 
forms of ALS and current research on targeted treatments.
Keywords: motor neuron disease, antisense oligonucleotide, amyotrophic lateral 
sclerosis, primary lateral sclerosis, novel therapies, genetics, trials
1. Amyotrophic lateral sclerosis
1.1 History of ALS
The earliest known description of motor neuron disease was in 1824 by Charles 
Bell, although it may have been described even earlier. The term amyotrophic 
lateral sclerosis was coined by Jean-Martin Charcot in his paper in 1874, where he 
described the condition and its connection to underlying neurological problems [1]. 
In 1886, Alfred Vulpian described the flail arm presentation of ALS. In 1918, Pierre 
Marie and his student, Patrikios, described the flail leg presentation of ALS. In 
1945, the US Navy reported ALS concomitant with dementia and parkinsonism in 
Guam. Later, in 2011, we would know that this is due to the C9ORF72 mutation [2]. 
In the 1969, electrodiagnostic criteria were established for the diagnosis of ALS and 
updated in 2008 [3]. In 1990, the El Escorial criteria for diagnosis were established 
at the World Federation of Neurology meeting [4]. The first mutation related to 
ALS identified was the SOD1 mutation in 1993. As a result of this discovery, mouse 
models were created and the first medication for ALS was developed, riluzole. In 
2015, the second ALS medication, edaravone, was approved [2].
1.2 Epidemiology
The most common motor neuron disease is ALS with an incidence of up to 8 per 
100,000 people worldwide [5]. On average, the age of onset is 56 in sporadic ALS 
and 46 in familial ALS. Men are more likely to develop ALS than women. Disease 
duration has been quoted to be 3 years, on average; however, this is extremely 
variable, and it is impossible to predict the rate of decline. Cause of death is usually 
respiratory failure [2].
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1.3 Symptoms
There are several clinical phenotypes that describe the symptom onset of amyo-
trophic lateral sclerosis. The classic (Charcot) phenotype is characterized by limb 
onset with pyramidal signs, which are not predominant [6]. This includes patients 
who have onset in the proximal legs. The flail arm phenotype has progressive proxi-
mal weakness and wasting in the arms for at least 12 months before the involvement 
of the legs or bulbar [6]. By contrast, patients with the flail leg phenotype have 
progressive distal onset of weakness and wasting in the legs and feet for 12 months 
before the involvement of the arms or bulbar. These patients are more likely to have 
an SOD1 mutation, with an odds ratio of 3.75 [6].
Predominantly upper motor neuron (UMN) ALS has pyramidal signs, such as 
severe spastic para- or tetraparesis [6]. Upper motor neuron signs, such as Babinski, 
Hoffmann and hyperactive reflexes or jaw jerk, are present [6]. These patients also 
have dysarthria or pseudobulbar affect and must show clear signs of lower motor 
neuron disease to differentiate them from primary lateral sclerosis [2]. This is indi-
cated by muscle weakness or wasting, or by the presence of denervation on EMG 
in at least 2 different muscles [3]. These patients are more likely to have a TARDP 
mutation, with an odds ratio of 2.65 [6].
The bulbar phenotype has a bulbar onset of disease, characterized by dysarthria 
or dysphagia. They have wasting of the tongue with fasciculations on examination, 
and they seem to spare the limbs for at least 6 months [6]. This phenotype is more 
typically seen in patients with the C9ORF72 mutation with an odds ratio of 2.39 [6]. 
Finally, in the respiratory phenotype, prevalent respiratory impairment is appar-
ent at onset. This may include orthopnea or dyspnea on exertion or at rest. Upper 
and lower motor neuron signs in this subgroup are mild in the first 6 months of 
disease [6].
1.4 Diagnosis
The El Escorial criteria are used to make the diagnosis of ALS [2]. They are 
broken down into possible, probable or definite ALS. The criteria require progres-
sion of upper and lower motor neuron deficits [4]. The signs can be clinical or 
electrodiagnostic (laboratory-supported ALS has been incorporated into the other 
categories) [3]. Definite ALS is defined by the combination of upper and lower 
motor neuron signs in three regions of the body, including limbs (each limb is a 
region) and bulbar. In probable ALS, only two regions are required, although at 
least one upper motor neuron sign should be more rostral. In possible ALS, only 
one region of both upper and lower motor neuron signs is needed. Alternatively, 
two regions of the upper motor neuron signs are caudal to the lower motor neuron 
signs [4].
Electrodiagnostic criteria of ALS have been established [3]. CMAPs should be no 
less than 75% of their normal value and reduction of amplitude between two points 
of stimulation should not be more than 30%, as this would constitute a conduc-
tion block [3]. Motor latencies and durations should be normal, or not more than 
1.5 times the upper limit of normal [3]. F-response latencies should not be more 
than 1.3 times the upper limit of normal [3]. There should be no conduction block, 
as this is a sign of multifocal motor neuropathy [2]. Sensory evoked potentials 
should be normal in ALS [2]. On electromyography, there should be positive sharp 
waves, fibrillation potentials and/or fasciculation potentials in at least 2 regions 
[3]. Chronic neurogenic changes, such as motor unit configuration of increased 
duration/amplitude, polyphasia, early/reduced recruitment and increased envelope 
amplitude of interference pattern, are expected to be present [3].
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The differential diagnosis of ALS is broad and includes infectious, inflamma-
tory, paraneoplastic and toxic/metabolic causes [7]. Benign fasciculation syndrome 
is a common differential to ALS. The fasciculations in benign fasciculation syn-
drome are exacerbated by exercise, anxiety, caffeine, thyrotoxicosis and alcohol [7]. 
Only a small subset of patients who present with fasciculations progress to include 
other motor neuron signs. Calf fasciculations are particularly benign in nature. On 
electromyography, the fasciculations in ALS can double, are shorter in duration, 
have polyphasia and have a higher firing rate than those in benign fasciculation 
syndrome [4].
Multifocal motor neuropathy with conduction block has a prevalence of 0.6 
per 100,000 people, which is 10 times rarer than ALS. Compared with ALS, there 
is a slower progression and younger onset age, and it tends to be more distal with 
minimal wasting [7]. Wrist drop or finger drop is a common presentation. Sensory 
system is not involved, unless this is a rarer form, such as MADSAM [2]. Reflexes 
are variable and can be brisk in up to 20% of patients. There is no bulbar or respira-
tory involvement [7]. The presence of conduction block on motor nerve conduc-
tion studies or triple stimulation technique (TST) is significant. Multifocal motor 
neuropathy and its subtypes are treatable with IVIG [2, 7].
Chronic inflammatory demyelinating polyradiculopathy has a motor predomi-
nant form that can mimic ALS [2]. The disease is symmetric with a relapsing and 
remitting course, which distinguishes it from ALS [7]. CSF protein elevation is 
important in its diagnosis and treatment is IVIG [2, 7].
Inclusion body myositis is a myopathy that mimics the anterior horn disease. 
Involvement of specific muscle groups, including quadriceps, wrist and finger flex-
ors, is suspicious for this disease [2]. About 5% of these patients can have overactive 
reflexes and up to 40% can have fasciculations [7]. To further complicate things, 
electrodiagnostic studies of these patients can look more neurogenic than myogenic 
[7]. Quantitative motor unit analysis of the quadriceps is most sensitive in revealing 
a myogenic pattern with short duration units [7]. Muscle biopsy is diagnostic [2]. 
There is no treatment for inclusion body myositis [2].
Spinobulbar muscular atrophy is a different motor neuron disease caused by an 
x-linked polyglutamine mutation with CAG repeats in the androgen receptor gene 
[2]. This makes the androgen receptor less functional and causes atrophy and weak-
ness in bulbar and limb girdle muscles [2]. Endocrine signs, such as gynecomastia, 
diabetes mellitus and testicular atrophy, differentiate this from ALS [7]. There is no 
treatment for spinobulbar muscular atrophy [2, 7].
Primary progressive multiple sclerosis can mimic ALS; however, this is easily 
excluded with MRIs of the neuroaxis or the presence of oligoclonal bands in the CSF 
[7]. Myasthenia gravis, particularly MUSK, may mimic ALS [7]. Myasthenia gravis 
is characterized by fatigable weakness, differentiating it from the weakness of ALS 
[2]. Serum antibody testing can differentiate myasthenia gravis from ALS [7].
Infectious causes of motor neuron mimic syndromes include human 
T-lymphotropic virus (HTLV) and West Nile virus, as well as post-poliomyelitis 
syndrome [7]. Polio infections affect the anterior horn cells [2]. West Nile virus has 
an associated myelitis, among other neurologic symptoms [2]. HTLV causes a demy-
elinating upper motor neuron disease called tropical spastic paraparesis [7]. Bladder 
dysfunction and sensory changes differentiate this from ALS [7].
1.5 Current treatments
The mainstay of treatment at this time is riluzole [2]. Edaravone is also approved 
for the treatment of ALS; however, its intravenous administration and requirement 
of a port leads to complications [8]. An oral form of Edaravone is being developed. 
Neurodegenerative Diseases - Molecular Mechanisms and Current Therapeutic Approaches
4
A third approved drug, a combination of dextromethorphan and quinidine, has 
been beneficial for pseudobulbar affect and other bulbar dysfunction in ALS [2].
Respiratory function is monitored using forced vital capacity (FVC) every 
3 months [9]. It is more accurately done lying down [9]. Unfortunately, FVC is not 
a good measure of early respiratory decline and can be confounded by the inability 
to create an adequate seal on the mouthpiece [9]. Respiratory failure in ALS is best 
treated with the use of noninvasive ventilation (NIV) [2]. These methods include 
cough assist early on and then may advance to BiPAP [9]. Invasive ventilation, 
such as intubation and tracheostomy, are options for emergent respiratory support 
or severe respiratory failure in ALS; however, there will be a difficult decision to 
withdraw invasive respiratory support, should the patient worsen. Early discussion 
of advanced directives (before dementia or inability to communicate) is essential to 
prevent unwanted invasive procedures in an emergency [9].
Physical and occupational therapy can help improve function by training 
patients in compensatory skills and providing assistive devices for every step of the 
way. A study that looked at exercise in ALS showed there is no risk of worsening 
disease with moderate exercise [10]. Low-impact aerobic exercises can improve 
cardiovascular health and decrease depressive symptoms [10]. Speech-language 
pathology is important for tracking bulbar dysfunction and giving advice on how to 
speak more clearly or modify foods and drink to prevent choking [10].
Maintaining weight using a high-calorie diet has been shown to improve quality 
of life and survival in patients with ALS [11]. More studies on which macronutri-
ents are most beneficial are needed, although current studies show that high-fat 
and high-cholesterol diets are beneficial [11]. If bulbar dysfunction progresses to 
the point where the patient cannot eat or drink without choking, or if the patient 
loses more than 5% of his or her body weight between visits (3 months), a feeding 
tube (usually a percutaneous endoscopic gastrostomy, or PEG) is recommended 
[11]. Unfortunately, there is weak evidence that PEG tubes prolong survival, despite 
benefits of reducing weight loss, preventing dehydration and administration of 
medications [11].
The future of directed treatments for ALS is bright. Later in this chapter, I will 
discuss research into the treatment of genetic ALS.
2. Genetic amyotrophic lateral sclerosis
About 10% of ALS cases are genetic [2]. Most are autosomal dominant, although 
they can be recessive or X-linked [2]. Over 30 genes related to ALS have been dis-
covered so far. The most common of these are C9ORF72 (about 30% in Europeans 
and 2.3% in Asians), SOD1 (14.8% in Europeans and 30% in Asians), TAR DNA-
binding protein (4.2% in Europeans and 1.5% in Asians) and fused in sarcoma 
(2.8% in Europeans and 6.4% in Asians) [12]. Ubiquilin2 (UBQLN2), ALSIN, 
senataxin (SETX), spatacsin, vesicle-associated membrane protein-associated 
protein B (VAPB), angiogenin (ANG), factor-induced gene 4 (FIG 4), optineurin 
(OPTN) and “other unknown genes” account for the rest [2]. Only a few of these, 
such as C9ORF72, are causal. The rest are disease-modifying genes [12].
2.1 C9ORF72 and SETX
C9ORF72 is a protein differentially expressed in normal and neoplastic cells, 
which modulate (via Rab or Ras GTPase) endosomal trafficking and autophagy in 
primary neurons [12, 13]. The gene is located on chromosome 9p21.2 and is a hexa-
nucleotide repeat of GGGGCC [2]. In a healthy person, there are 20–30 repeats; 
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however, someone with the mutation can have hundreds of repeats [13]. Although 
anticipation is shown in trinucleotide repeat disorders, it has not been demon-
strated in hexanucleotide repeat disorders [14]. Repeats are typically expanded in 
multiples of 3 to preserve the genetic reading frame [15]. Most repeat disorders 
do not cause catastrophic frame shift mutations, unless a stop codon is the triplet 
added [15]. There is a transitional number between the normal number of repeats 
to the permutation and finally to the number of repeats that determine a mutation, 
although exact numbers are currently not agreed upon in ALS [13].
Typically, after inheritance of a repeat expansion, it remains dormant in the 
cell [13]. As the cells divide, the repeats tend to continue to expand when more 
repeats are copied onto the daughter strands during replication [13]. Repeat DNA 
is more susceptible to damage [15]. Fibroblasts and lymphocytes from patients 
with Huntington’s disease, ALS, Alzheimer’s disease and Parkinson’s disease all 
have DNA that is relatively sensitive to ionizing radiation and chemical muta-
gens [15]. When the damaged DNA is repaired, more repeats are created during 
DNA repair [15]. Mismatch and base-excision repair cause somatic expansion 
of repeated sequences of trinucleotide repeat disorders [15]. As this in more 
cells, the organism eventually reaches a critical point at which a significant 
number of cells meet the threshold number of repeats to produce disease [13, 15]. 
Progression of disease occurs when more cells reach this threshold and enter a 
pathologic state [13, 15].
Repeat expansion mutations in the C9ORF72 gene, such as the hexanucleotide 
repeat seen in ALS, lead to the formation of R-loops in the DNA [16]. R-loops are 
a hybridization of mRNA with dsDNA with looped intron sequences, which have 
been spliced out of the mRNA during the transcription process [16]. R-loops occur 
naturally in several cellular processes, including mitochondrial DNA replication, 
and in the transcription bubble [16]. R-loops have been thought to rarely occur as 
transcriptional by-products but are more common than once thought [16]. Others 
believe that R-loops are natural intermediates of transcription that are eliminated 
by Senataxin [17].
RNA:DNA hybrids are more stable than dsDNA [16]. High G-content (like 
in the C9ORF72 hexanucleotide repeat) encourages and stabilizes R-loops by 
facilitating the opening of the transcriptional bubble while DNA strands are still 
separated [16]. SETX is one of the genes involved in terminating transcription 
and senataxin depletion (such as in SETX ALS) correlates with the accumulation 
of RNA:DNA hybrids [17]. The mRNA would usually move out of the nucleus and 
not interact with the dsDNA as much; however, this mRNA becomes sequestered 
in the nucleus [16]. This enlarges the nucleolus and recruits the cell DNA damage 
response [16]. If unsuccessful, the DNA damage response will signal for apoptosis 
of the neuron [16].
Haploinsufficient proteins form from translated GGGGCC introns that are not 
degraded after splicing [18]. These are exported out of the nucleus by an unknown 
mechanism and translated in the cytoplasm [18]. The resulting haploinsufficient 
C9ORF72 protein forms toxic dipeptide aggregates that accumulate in the neuron 
[18]. These haploinsufficient proteins may have properties of prions [18].
2.2 SOD
SOD (superoxide dismutase) is a cytoplasmic enzyme of 153 amino acids: one 
copper atom for function and one zinc atom for structural stability [18]. It converts 
oxygen radicals into peroxide and oxygen [18]. The cell is then able to turn the 
peroxide into water and oxygen with catalase [18]. This is an extremely stable pro-
tein, but can unfold from dimer to two unfolded monomers via a folded monomer 
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intermediate step [18]. A complex combination of molecular pathways and cell 
interactions cause ALS [2]. Oxidative stress, aberrant RNA processing and protein 
misfolding/insoluble proteins have all been implicated in motor neuron degenera-
tion in ALS [2]. This is an example of an oversimplified mechanism of SOD1-
mediated ALS. Microglia secrete cytokines, stimulating inflammation by recruiting 
astrocytes [18]. Astrocytes come and release nitric oxide and prostaglandin E2 [18]. 
SOD comes to convert NO into peroxide and oxygen [18]. In ALS patients, the SOD 
that arrives is mutated and aggregates, leading to endoplasmic reticulum (ER) stress 
[18]. The ER helps with endosomal trafficking, so defective endosomal trafficking 
causes organelle disruption, including mitochondrial disruption, and activates 
apoptosis of the neuron [18]. ER stress also causes dysfunction in axonal transport, 
leading to axonal loss [18].
The SOD1 gene is located on chromosome 21q22 [2] and contains 5 exons [18]. 
About 150 mutations of this gene have been identified, which are predominantly mis-
sense mutations, but also include nonsense mutations, insertions and deletions [2]. 
Notable mutations in this group include SOD1A4V-ALS for its rapid clinical progres-
sion, SOD1A89V-ALS for its sensory neuropathy, SODI113T-ALS for its diversity of 
phenotype and SOD1G93A-ALS for its use in transgenic mice [2, 18]. The SOD1D90 
mutation is recessive in Scandinavians, but dominant in other groups [18]. SOD1 
knockout mice do not develop clinical ALS [18]. Instead, they develop age-dependent 
distal motor neuropathy, suggesting a toxic gain of function in the SOD [18].
2.3 FUS and TAR DNA-binding protein
FUS is a DNA- and RNA-binding protein that repairs damage and breaks, 
especially double-strand breaks in DNA [19, 20]. Loss of function mutations in FUS 
gene (16p11.2) lead to impairment of the poly(ADP-ribose) polymerase (PARP)-
dependent DNA damage response, leading to increased DNA damage, especially in 
neurons [19]. The mutated FUS aggregates [19]. In ALS, the mutations are located 
in the nuclear localization sequence in the c-terminus [19]. This causes FUS to 
lose its ability to stay in the nucleus and the mutated FUS will instead aggregate 
in the cytoplasm [19]. ALS due to the TARDBP gene has a similar mechanism also 
with cytoplasmic aggregates [20]. Inclusion bodies that are FUS positive, TDP-43 
negative may be found [19]. The typical phenotype for FUS-ALS is a lower motor 
neuron predominant syndrome without bulbar involvement [2]. They may have 
frontotemporal dementia as well [2]. The typical age at onset ranges from as young 
as the mid-twenties to as late as the eighth decade of life [2]. Mean duration of this 
form of ALS is 33 months [2].
3. Genetic treatments
3.1 CRISPR
CRISPR (clustered regularly interspaced short palindromic repeats) was dis-
covered in 1987 in Osaka by Ishino et al. in E. coli, although their significance was 
unknown [21]. The CRISPR/Cas system is a part of the prokaryotic immune system, 
allowing resistance to foreign genetic data from bacteriophages [21]. Archaea and 
bacteria use CRISPR/Cas to find bacteriophage DNA that has been entered into its 
genome and remove it [21].
There are three steps of CRISPR/Cas-mediated immunity [21]. The first step 
is adaptation [21]. Prokaryotes place protospacers in their DNA made up of pieces 
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of foreign DNA (from phages and plasmids that previously invaded) attached 
to palindromic repeats [21]. The second step is expression with maturation [21]. 
Transcription of the protospacers and repeats yields a precursor CRISPR-RNA, 
which will mature into the guide RNA (gRNA) [21]. The third step is interference 
[21]. Once mature, the guide RNA is used in the CRISPR/Cas system to recognize 
and create a double-strand break by foreign DNA [21].
Pieces of foreign DNA are stored by the prokaryote in the form of a genetic 
library of phages and plasmids, which have previously invaded [21]. Cas (CRISPR-
associated protein) scans bacterial DNA for bacteriophage DNA that matches 
the guide RNA attached to CRISPR and cleaves it, when found [21]. Cas is a DNA 
endonuclease that allows for unwinding of DNA, checking for sites complemen-
tary to the guide RNA (20 BP spacer region) [21]. Once a match is found, it cleaves 
both strands of the DNA [21]. When the cell attempts to repair the break, muta-
tions are often introduced, deactivating the viral gene [21]. The repair can be done 
via nonhomologous end joining (NHEJ), which can be done at any point in the cell 
cycle. In certain stages of the cell cycle, homology-directed repair (HDR) occurs, 
allowing for more precise DNA repair [21]. Researchers have been working on 
enhancing this type of repair for high-fidelity CRISPR/Cas-mediated gene editing 
[22]. This process can be manipulated for gene inactivation or insertion of foreign 
DNA [22]. Mammalian cells predominantly rely on nonhomologous end joining 
for DNA repair, which is error-prone, resulting in insertion and deletion (indels) 
mutations [21]. Specifically in neurons, which are terminally differentiated post-
mitotic cells, homology-directed repair is limited, but nonhomologous end joining 
is easier [22].
3.2 Use of CRISPR in eukaryotes
In 2012, Jennifer Doudna from UC Berkeley and Emmanuelle Charpentier from 
Umea University in Sweden demonstrated the use of CRISPR/Cas for human con-
trolled genetic editing [21]. She fused CRISPR RNA (crRNA) with trans-activating 
CRISPR RNA (tacrRNA) to form a chimeric single-guide RNA (sgRNA) to allow 
for site-specific gene editing in a eukaryote [21]. This method is popular due to its 
low cost and ease of production in a lab [21]. Since then, research in CRISPR has 
expanded to include every species: from attempts to drive malaria-carrying mos-
quito species to extinction to combating antibiotic resistance to agriculture, making 
crops hardier [21].
Unfortunately, the CRISPR/Cas9 system is not specific enough to prevent it 
from cleaving nontarget DNA [21]. DNA does not have to fully match the guide 
RNA (can tolerate 3–5 mismatches) for it to introduce a double-strand break, which 
leads to unpredictable mutations [21]. Researchers have been working to increase 
the specificity of CRISPR/Cas9 systems by using two guide RNAs or shorter 
(truncated) guide RNAs [22]. Decreasing the GC content of guide RNAs also helps 
specificity [23]. Adding a short-lived ribonucleoprotein to the CRISPR-Cas9 system 
decreases off-target effects by allowing the complex to break down after a short 
period of activity [22]. This allows for more locally acting gene editing. There is also 
the possibility of introducing the Cas protein instead of the Cas gene into a subject, 
so the effect on the genome is shorter-lived [22].
There are other downsides, including immune attacks on the system, due to 
its bacterial origin [21]. PEGylation, the modification of biomolecules by adding 
polyethylene glycol (PEG), a nontoxic, nonimmunogenic polymer, is one method to 
circumvent immune attack [21]. Humanization of the proteins is another method of 
circumventing this problem [22].
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3.3 Cas modification and types
The Cas protein may be modified in many different ways, including deactivat-
ing one or both cutting domains and adding deaminases, transcriptional activa-
tors or blockers (dCas-sgRNA) [22]. Deactivating one of the cutting domains, 
creating a ‘nick’ instead of a ‘break,’ prevents unwanted damage in off-target 
sites [22]. One may opt to deactivate both cutting domains (dead Cas or dCas) 
and attach other enzymes to the complex, such as deaminases, which cause point 
mutations [22]. These point mutations may include stop codons to prevent tran-
scription of a disease gene (CRISPR interference CRISPRi), or they may change a 
disease-causing mutation to a healthy gene [23]. Transcriptional activators, such 
as VP64 or MS2 coat protein, may be added to recruit transcription machinery 
and promote transcription of specific genes (CRISPR activation or CRISPRa) 
[21]. CRISPRi is accomplished by adding a Kruppel-associated box (KRAB) 
domains to inactivate transcription by recruiting factors that physically block the 
gene [21].
Alternatively, one can use a different type of Cas. Each bacterial species has 
its own Cas protein, or multiple types of Cas [22]. Strep. pyogenes Cas9 (spCas9) 
was found first and is most commonly used in a CRISPR type II system, may be 
directed by two guide RNAs [22]. Cas9 cuts double-stranded DNA that matches the 
guide RNA [21]. Staph. aureus Cas9 (saCas9) is small, which allows it to fit inside 
adeno-associated virus, making it a convenient choice for that vector [24]. Strep. 
thermophilus Cas9 (stCas9) is more specific, requiring a match to not only the 
guide RNA but also a protospacer-adjacent motif (PAM) (a specific sequence next 
to the viral DNA) [24]. This prevents unwanted off-target effects. CasX is the small-
est known Cas so far and less immunogenic [25]. Jennifer Doudna discovered CasX, 
found in ground-dwelling bacteria, which are unfamiliar to the human immune sys-
tem and nonpathologic, decreasing the chance of immunogenicity [25]. Cas12 cuts 
double-stranded DNA that matches the guide, as well as all single-stranded DNA 
in a cell in a nonspecific way [21]. Cas13 cuts all single-stranded RNA in a cell [21]. 
Cas14 is found in Archaea and is very small [22]. It cuts all single-stranded DNA in a 
cell in a more specific way, with a system (DETECTR) that detects infectious organ-
isms and genetic mutations [22]. Cpf1 is an endonuclease that leaves an overhang on 
one side of the double-strand break (DSB), which promotes nonhomologous end 
joining in neurons [21].
Delivery methods for the CRISPR/Cas system include viral vectors, nanopar-
ticles, lipofectamine, nucleofection, microinjection, short-lived ribonucleoproteins 
and electroportation [23]. Some of these methods, including microinjection and 
electroportation, can damage cells and are not possible in vivo [23]. In electro-
portation, an electric field increases permeability of cell membrane, allowing 
entry of the CRISPR/Cas system into the cell [23]. Nucleofection, nanoparticles 
and lipofectamine are less commonly used by researchers due to the tendency for 
low cell penetrance using these methods [23]. Viral vectors are the most common 
and effective delivery systems. AAV (adeno-associated viral vector) is the most 
commonly studied vector [26, 27]. The limiting factors in the use of viral vectors 
are low cargo capacity, immunogenicity and tissue specificity [26]. AAV is a small 
virus that does not cause disease, just a very mild immune response [26]. It attaches 
and infiltrates the host cell. The virus transfers DNA into the nucleus, leading to 
sustained gene expression [26]. There is ~ 4.7 kb AAV vector packaging limit [26]. 
Therefore, when using this delivery system with spCas9, two AAVs are required: 
one to package spCas9 and the other to package the sgRNAs [26]. With smaller Cas 
types, such as saCas9, only one AAV is required [26]. AAV is specific to muscle, 
liver, brain and eye tissue [27]. Immune response (mainly humoral, due to prior 
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infection with AAV) was found in 96% of patients in one study [27]. These patients 
demonstrated antibodies for AAV [26, 27]. Other delivery systems use other viruses, 
such as adenovirus and lentivirus [26]. Short-lived ribonucleoproteins (RNP) are 
proteins that shuttle the CRISPR-Cas system into a cell [27]. Since they are short-
lived, the action of the CRISPR-Cas system tends to be local to where the RNPs are 
injected [27]. These decrease off-target effects and are less immunogenic than viral 
vectors [23].
3.4 Antisense oligonucleotides
Antisense oligonucleotides (ASOs) are synthetic nucleic acid sequences that 
bind RNA to modulate gene expression [28]. ASOs can restore protein function 
by splice modification, decrease aberrant protein function by silencing, modify 
protein function or reduce toxicity of an aberrant protein [28]. ASOs penetrate their 
target with the help of ribose alteration, avoid degradation by nucleases and avoid 
immune response by alterations in their phosphate group, ribose and nucleosides 
[28]. Two ASOs were FDA approved in 2016: eteplirsen for Duchenne muscular 
dystrophy and nusinersen for spinal muscular atrophy [28]. Proteinuria has been a 
common side effect with the ASOs, although it has been mostly benign [28].
About 14% of patients who have Duchenne muscular dystrophy contain the 
mutation at exon 51, where eteplirsen takes action [29]. It works by mRNA knock-
down via activation of RNA-H, which breaks down the RNA-DNA complex before 
translation [29]. It aims to skip the mutated exon to convert the frame shift muta-
tion back into the reading frame [29].
Nusinersen works via alteration of gene splice site [30]. It targets intronic splic-
ing silencer N1 (ISSN1), causing inclusion of exon 7 in SMN2 pre-mRNA [30]. This 
results in SMN2 protein translation that looks identical to SMN1 protein [30].
CRISPR-Cas systems have some benefit over ASOs, such as being less cytotoxic 
and requiring less number of treatments [23].
3.5 Other methods of genetic manipulation
Meganucleases are large endonucleases, able to cut out large, 14–40 base pair 
(BP) long, DNA sequences [31]. They were discovered in the 1980s [31]. Although 
these are specific, they are costly to create, requiring expertise and more time 
than CRISPR, which makes it inefficient [31]. Meganucleases have been studied in 
Duchenne muscular dystrophy [31]. One group designed a meganuclease that cuts 
upstream of the deletion ‘hot spot’ of intron 44 of the dystrophin gene [31]. It was 
delivered via a lentiviral vector [31]. After administration, expression of a fully 
corrected dystrophin gene was observed via western blot [31].
Zinc finger nucleases recognize short sequences (3 BP) of DNA, but can be 
combined with several other zinc fingers to accommodate longer sequences [32]. 
They are less specific, but are expensive to make as they require expertise, time and 
effort to create [32]. They are cytotoxic to cells, so currently, they are mainly in use 
for modifying stem cells and immune cells [32]. Ousterout et al. used this technol-
ogy in myoblast cell cultures to yield dystrophin expression [32].
Transcription activator-like effector nuclease (TALEN) are artificial restriction 
enzymes, fused to a nuclease and designed to recognize specific DNA sequences of 
33 or 34 amino acid repeats [33]. They are able to perform DNA repair, replacement, 
insertion or deletion [33]. This is a precise method that is easy to make and is not 
costly [33]. TALEN has been used successfully in human cell cultures (myoblasts 
and dermal fibroblasts) with Duchenne muscular dystrophy, as well as to treat 
Golden Retrievers with muscular dystrophy [33].
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RNA interference (RNAi) is used in the cell to control gene expression [34]. Two 
types of RNAs are known to perform this function: small interfering RNAs (siRNA) 
and microRNAs (miRNA) [34]. After RNA polymerase II produces mRNA, the 
mRNA travels to the cytoplasm for transcription, unless it is intercepted by RNA 
interference [34]. siRNA or miRNA binds to enzymes that break down mRNAs that 
match or closely match a sequence in them [34]. miRNAs are about 21 nucleotides 
long and bind to dicer, an enzyme that cleaves mRNA that matches the single-
stranded microRNA [34]. After cleavage, the mRNA is degraded [34]. Argonaut is 
another enzyme that performs the same function [34]. Once bound to miRNA or 
siRNA, the complex is called RISC (RNA-induced silencing complex) [34]. siRNAs 
differ from miRNAs in that they are double stranded [34]. RNAi requires multiple 
treatments and can be cytotoxic [34].
4. Use of genetic treatments in treating motor neuron disease
4.1 CRISPR treatment of ALS
Treatment of ALS has been limited by the limited understanding of the mecha-
nism of disease [2]. Some of the use of CRISPR/Cas9 research done in ALS is to 
identify the mechanism by which the various genes cause toxicity, discovering 
modifiers and RNA-processing pathways [35].
Researchers did a proof of concept study, which demonstrated that using 
CRISPR/Cas9 in an AAV delivery system in G93A-SOD1 mice targeting the SOD1 
mutation has delayed onset, increased survivability of motor neurons, decreased 
motor atrophy, increased motor function and prolonged lifespan, compared to 
control mice [36]. G93A-SOD1 transgenic mice were infused at birth or first day of 
life with the delivery system [36]. Typically, the mice develop symptoms at 90 days 
of life [36]. A single peptide is changed in the SOD1 mutation in this model [36]. 
The amount of mutant SOD1 protein in the spinal cord was reduced by the infusion, 
compared with control mice [36]. This delayed the onset of disease by a range of 
2–36 days, but did not slow disease progression once the onset came [36]. However, 
the delay in onset prolonged survival in test mice by 25%, compared to diseased 
controls [36].
Another group was able to produce gene-corrected fibroblast stem cells using a 
CRISPR/Cas9 system from ALS patients with SOD1 and FUS mutations [37]. They 
first collected and cultured FUS and SOD1-mutated fibroblasts and confirmed their 
mutations [37]. Then, they used a CRISPR/Cas system with electroportation to 
target the FUS mutation for correction with single-stranded oligodeoxynucleotide 
as a repair template [37].
In 2017, researchers demonstrated that they could use genetically modified 
mesenchymal stem cells to express neurotrophic factors [38]. Neurotrophic factors 
are peptides that promote growth, survival and differentiation of neurons [38]. 
This paper proposes that CRISPR/Cas in an AAV delivery system is a good way 
to genetically modify mesenchymal stem cells to express these factors, which are 
neuroprotective [38].
Other researchers are looking at using CRISPR/Cas13 to target aberrant mRNAs 
in C9ORF72 ALS patients [39]. CRISPR/Cas13 cuts RNA and this group modified 
it to be more specific toward the toxic mRNAs, which do not leave the nucleus and 
lead to R-loops in DNA [39]. Their mouse models have shown improvement in 
motor symptoms [39].
This group [40] was able to eliminate toxic microsatellite repeat expansion RNAs 
with an RNA-targeting Cas9 in myotonic dystrophy cell cultures. They developed 
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a programmable CRISPR/Cas9 system to visualize and eliminate repetitive RNAs 
retained and aggregating in the nucleus [40]. Although these experiments were 
conducted in myotonic dystrophy cell cultures, not cell cultures expressing 
C9ORF72, they are theoretically applicable [40].
In 2018, a group did a genome-wide survey, looking for suppressors and enhanc-
ers of C9ORF72 dipeptide repeat toxicity in human cells [41]. These were validated 
using primary mouse neurons with CRISPR/Cas9 screening [41]. They discovered 
several modifiers, but one in particular, called TMX2, modulated the endoplasmic 
reticular stress caused by C9ORF72 dipeptide repeats, increasing survival to 100% 
(from 10%) in their mouse models [41].
Additional researchers used a SaCas9 endonuclease to disrupt HERV-K env, a 
retroviral gene, human mouse mammary tumor virus-like 2, related to prostate 
cancer motor neuron disease [42]. They found this inhibited molecules involved in 
amyotrophic lateral sclerosis, including epidermal growth factor receptor (EGF-R), 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), SF2/ASF 
and TDP-43 [42]. These molecules are important for RNA-binding and alternative 
splicing [42].
4.2 ASO editing of ALS
Tofersen is an antisense oligonucleotide that binds to the mRNA from the SOD1 
gene [43]. This drug is being studied in patients with ALS caused by the SOD1 
mutation [43]. In the phase 1/2 trial, treatment with tofersen 100 mg in 10 patients 
with SOD1 fALS over a three-month period resulted in a statistically significant 
lowering of SOD1 protein levels in the cerebrospinal fluid and a slowed decline in 
the ALS Functional Rating Scale-Revised (ALSFRS-R) compared to 12 patients 
receiving a placebo [44]. They also noted slowed decline in muscle strength and 
vital capacity in the study group [44].
5. Conclusion
Amyotrophic lateral sclerosis is a disease with no cure; however, current research 
is promising for a cure in the near future. Technologies in genetic editing show par-
ticular promise in the field of neurodegeneration. Molecular mechanisms of genetic 
diseases, even those with known mechanisms, are oftentimes much more complex 
than initially thought. Discoveries regarding transcription modulators have proven 
particularly useful in research to find treatments for ALS. Given the recent advances 
in these areas, the future appears brighter for patients with ALS.
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